Completion of Retail Entitlement Offer
Filed with ASX · · 3 pages · English
Summary by 6ix AI
PYC Therapeutics Limited has announced the completion of its retail entitlement offer for new shares, following an earlier institutional component that raised significant funds. New shares are expected to be issued shortly and will rank equally with existing shares, while the company retains the right to place any unallocated shares within a specified period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- PKD Clinical Trial - Approval to Escalate Dosing
- Half Yearly Report and Accounts
- Retail Offer Booklet
- Completion of Placement and Institutional Entitlement Offer
- PYC Raising up to $653m to Deliver Human Efficacy Data
Later from PYC Therapeutics
- ADOA Program - SRC Approve Progression to Multi-Dose Study
- Presentation of Ophthalmology Clinical Trial Data at ARVO
- PKD - Initiation of Multiple Dose Clinical Trial
- ADOA Program Update
- PKD - Safety Committee Approves Dose Escalation
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics